Vaxart

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2004-01-01

Employees: 109

Market Cap: $202M

Website: http://www.vaxart.com

Introduction: Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in March 2004 and is headquartered in South San Francisco, CA.

Clinical Trials

A Study to Evaluate VXA-CoV2-3.1 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

Phase 2

Recruiting

Conditions: SARS-CoV2
COVID-19

Interventions: Biological: VXA-CoV2-3.1
Biological: COMIRNATY®

First Posted Date: 2024-11-04

Last Posted Date: 2024-11-04

Lead Sponsor: Vaxart

Target Recruit Count: 10000

Registration Number: NCT06672055

Locations: 🇺🇸
Pinnacle Research Group, Anniston, Alabama, United States
🇺🇸
Core Clinical Trials - Central Alabama Research LLC, Birmingham, Alabama, United States
🇺🇸
Coastal Clinical Research, Mobile, Alabama, United States

and more 142 locations

A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers

Phase 2

Active, not recruiting

Conditions: Norovirus Infections

Interventions: Drug: Placebo
Drug: Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose
Drug: Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose
Drug: Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose

First Posted Date: 2022-11-25

Last Posted Date: 2024-06-21

Lead Sponsor: Vaxart

Target Recruit Count: 135

Registration Number: NCT05626803

Locations: 🇺🇸
Johnson County Clin-Trials, Lenexa, Kansas, United States
🇺🇸
Nucleus Network Pty Ltd, Saint Paul, Minnesota, United States
🇺🇸
Ark Clinical Research, Long Beach, California, United States

A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers

Phase 1

Completed

Conditions: Norovirus Infections

Interventions: Biological: VXA-G1.1-NN

First Posted Date: 2022-01-28

Last Posted Date: 2024-06-21

Lead Sponsor: Vaxart

Target Recruit Count: 8

Registration Number: NCT05213728

Locations: 🇺🇸
AltaSciences LA, Cypress, California, United States

Norovirus Challenge Study

Phase 1

Completed

Conditions: Norovirus Infections

Interventions: Biological: VXA-G1.1-NN
Other: Placebo Tablets
Biological: Norovirus GI.1 Norwalk Virus Inoculum

First Posted Date: 2022-01-27

Last Posted Date: 2024-06-21

Lead Sponsor: Vaxart

Target Recruit Count: 165

Registration Number: NCT05212168

Locations: 🇺🇸
AltaSciences LA, Cypress, California, United States

A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine

Phase 2

Completed

Conditions: COVID-19

Interventions: Drug: VXA-CoV2-1.1-S
Other: Placebo Tablets

First Posted Date: 2021-10-05

Last Posted Date: 2024-06-21

Lead Sponsor: Vaxart

Target Recruit Count: 66

Registration Number: NCT05067933

Locations: 🇺🇸
Velocity Clinical Research, Inc,, Cleveland, Ohio, United States
🇺🇸
AMR Knoxville, Knoxville, Tennessee, United States
🇺🇸
AMR Wichita East, Wichita, Kansas, United States

and more 1 locations

Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines

Phase 1

Completed

Conditions: Norovirus Infections

Interventions: Biological: VXA-G1.1-NN

First Posted Date: 2021-05-06

Last Posted Date: 2024-05-22

Lead Sponsor: Vaxart

Target Recruit Count: 30

Registration Number: NCT04875676

Locations: 🇺🇸
WCCT Global, Inc., Cypress, California, United States

Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine

Phase 1

Completed

Conditions: Norovirus Infections

Interventions: Biological: VXA-GI.1.NN
Biological: Placebo Tablet

First Posted Date: 2021-04-22

Last Posted Date: 2023-02-13

Lead Sponsor: Vaxart

Target Recruit Count: 66

Registration Number: NCT04854746

Locations: 🇺🇸
Benchmark Research, Austin, Texas, United States
🇺🇸
WCCT, Cypress, California, United States

Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects

Phase 1

Completed

Conditions: Covid19

Interventions: Biological: VXA-CoV2-1

First Posted Date: 2020-09-24

Last Posted Date: 2024-06-21

Lead Sponsor: Vaxart

Target Recruit Count: 35

Registration Number: NCT04563702

Locations: 🇺🇸
WCCT, Cypress, California, United States

Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines

Phase 1

Completed

Conditions: Norovirus Infection

Interventions: Biological: VXA-G1.1-NN
Biological: VXA-G2.4-NS
Biological: Placebo Tablets

First Posted Date: 2019-04-01

Last Posted Date: 2022-09-21

Lead Sponsor: Vaxart

Target Recruit Count: 86

Registration Number: NCT03897309

Locations: 🇺🇸
Rapid Medical Research, Cleveland, Ohio, United States

Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers

Phase 1

Completed

Conditions: Norovirus Gastroenteritis

Interventions: Biological: VXA-G1.1-NN Oral Vaccine

First Posted Date: 2017-04-24

Last Posted Date: 2018-05-30

Lead Sponsor: Vaxart

Target Recruit Count: 66

Registration Number: NCT03125473

Locations: 🇺🇸
Celerion, Inc., Lincoln, Nebraska, United States

Home Terms & Conditions Privacy Policy